Long-read transcriptome sequencing of CLL and MDS patients uncovers molecular effects of SF3B1 mutations
Alicja PacholewskaiD, Matthias LienhardiD, Mirko BrüggemanniD, Heike Hänel, Lorina BilalliiD, Anja Königs, Felix Heß, Kerstin BeckeriD, Karl KöhreriD, Jesko KaiseriD, Holger GohlkeiD, Norbert GattermanniD, Michael J. HallekiD, Carmen HerlingiD, Julian KönigiD, Christina GrimmiD, Ralf HerwigiD, Kathi ZarnackiD, Michal R. SchweigeriD
Abstract
BackgroundMutations in splicing factor 3B subunit 1 (SF3B1) frequently occur in patients with chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS). These mutations have a different effect on the disease prognosis with beneficial effect in MDS and worse prognosis in CLL patients. A full-length transcriptome approach can expand our knowledge on SF3B1 mutation effects on RNA splicing and its contribution to patient survival and treatment options. ResultsWe applied long-read transcriptome sequencing to 44 MDS and CLL patients with and without SF3B1 mutations and found > 60% of novel isoforms. Splicing alterations were largely shared between cancer types and specifically affected the usage of introns and 3 splice sites. Our data highlighted a constrained window at canonical 3 splice sites in which dynamic splice site switches occurred in SF3B1-mutated patients. Using transcriptome-wide RNA binding maps and molecular dynamics simulations, we showed multimodal SF3B1 binding at 3 splice sites and predicted reduced RNA binding at the second binding pocket of SF3B1K700E. ConclusionsOur work presents the hitherto most complete long-read transcriptome sequencing study in CLL and MDS and provides a resource to study aberrant splicing in cancer. Moreover, we showed that different disease prognosis results most likely from the different cell types expanded during cancerogenesis rather than different mechanism of action of the mutated SF3B1. These results have important implications for understanding the role of SF3B1 mutations in hematological malignancies and other related diseases. HighlightsO_LILong-read transcriptome sequencing data enables the identification of > 60% of novel isoforms in the transcriptomes of CLL and MDS patients and isogenic cell lines. C_LIO_LISF3B1 mutations trigger common splicing alterations upon SF3B1 mutations across patient cohorts, most frequently decreased intron retention and increased alternative 3 splice site usage. C_LIO_LIMutation effect depends on alternative 3 splice site and branch point positioning that coincide with bimodal SF3B1 binding at these sites C_LIO_LIMolecular dynamics simulations predict reduced binding of SF3B1K700E to mRNA at the second binding pocket harboring the polypyrimidine tract. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 18
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mutated SF3B1 is associated with transcript isoform changes of the genes UQCC and RPL31 both in CLLs and uveal melanomas
Alejandro Reyes, Carolin Blume, … Wolfgang Huber·bioRxiv·Jul 13, 2014
- Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns
Alison D. Tang, Cameron M. Soulette, … Angela Norie Brooks·Nature CommunicationsPeer-reviewed·Mar 18, 2020
- SF3B1 mutation generates novel peptides from long non-coding RNAs
S. Bhattacharya, Mike Fernandez, … Lili Wang·bioRxiv·Oct 16, 2026
- Single-cell multi-omics defines the cell-type specific impact of splicing aberrations in human hematopoietic clonal outgrowths
F. Gaiti, P. Chamely, … D. A. Landau·bioRxiv·Jun 8, 2022
- CDK8 is a critical effector of cell fate dysregulation in SF3B1-mutant MDS
Elizabeth A. Bonner, Tun‐Yun Hsueh, … Stanley Chun-Wei Lee·bioRxiv·Aug 14, 2025
- SF3B1-mutant mis-splicing of UBA1 confers a targetable therapeutic vulnerability through UBA1 inhibition
Jonas Thier, Sophia Hofmann, … Vanessa Lundin·LeukemiaPeer-reviewed·Aug 26, 2025